|

PD-L1 t-haNK Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: NK-92

Pipeline

Phase 2: 2

Top Sponsors

  • ImmunityBio, Inc.1
  • Glenn J. Hanna1

Indications

  • Cancer2
  • Metastatic Head and Neck Cancer1
  • Recurrent Head and Neck Cancer1
  • Recurrent Head and Neck Squamous Cell Carcinoma1
  • Metastatic Head and Neck Squamous Cell Carcinoma1

El Segundo, California1 trial

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Chan Soon-Shiong Institute for Medicine (CSSIFM)

Phase 2

Boston, Massachusetts1 trial

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Brigham and Women's Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.